Brighter possibilities for treating blindness

June 05, 2019

Advances in preclinical research are now being translated into innovative clinical solutions for blindness, a review published in the 10th Anniversary Series of Science Translational Medicine depicts. (Science Translational Medicine 29 May 2019:Vol. 11, Issue 494, eaax2324; DOI: 10.1126/scitranslmed.aax2324)

The review authored by José Sahel, Jean Bennett and Botond Roska summarizes recent therapeutic strategies for treating blinding diseases which are very encouraging.

Review summary:

Gene replacement or gene editing strategies could potentially reverse vision loss and lead to close to normal visual outcomes. Early intervention during the early stages of retinal degeneration, when the photoreceptor cells (rods and cones) are still intact, is particularly promising. The first approved gene therapy for Leber congenital amaurosis (LCA) with confirmed biallelic RPE65 mutation has paved the way for more than 30 gene replacement trials worldwide in other conditions, e.g. those in clinical phase III for choroideremia, achromatopsia, and Leber hereditary optic neuropathy.

Gene-independent strategies aim to prevent or slow the progressive degeneration of photoreceptor cells with neuroprotective agents for a broad spectrum of retinal dystrophies. Neuroprotective strategies, particularly those for preserving cones, are the best approach for treating disease where there is ongoing photoreceptor cell degeneration.

Stem cell therapy, optogenetic therapy, and retinal prostheses are used to restore vision during the later stages of retinal degeneration. These approaches can be applied independently of the causal mutation and are expected to restore a low degree of vision in blind patients. Stem cell therapies to replace degenerated cells for restoring vision are under development or clinical evaluation in a wide range of retinal degenerative conditions, e.g. for the "non-neovascular" form (associated with gradual loss of photoreceptors and RPE cells) of age-related macular degeneration (AMD), for inherited retinal dystrophies (IRDs) and retinal pigment epithelium (RPE) replacement.

Brain-machine interface technologies using electrode arrays or optogenetics can stimulate the visual pathway downstream of the retina. Electrical stimulation of the primary visual cortex is one possible scenario that is currently in clinical trials.

Optogenetic therapy makes cells light sensitive through expression of an optogene encoding a light-activated channel or pump in the remaining inner retinal cells. It could be used to resensitize a degenerated retina to visible light independent of the mutation causing photoreceptor cell loss.

Retinal prostheses are able to reactivate remaining retinal circuits at the level of bipolar or ganglion cells after photoreceptor cell loss. Both epiretinal and subretinal implants are able to stimulate a light-insensitive degenerated retina and to restore partial vision in blind people.

Accelerating therapeutic developments in ophthalmology

Specific characteristics make the eye particularly suited for diagnostic and therapeutic exploration: easy access, small volume, high internal compartmentalization, and stable cell populations. The optical transparency of the eye allows direct visualization with high-resolution imaging and precise evaluation of disease stage and response to therapy. The relative immune privilege of the eye, especially the subretinal space, reduces adverse responses to injected vectors and gene products. However, progress in ophthalmology is intrinsically linked to increased understanding of the morphology and function of the visual system.
-end-


Institute of Molecular and Clinical Ophthalmology Basel

Related Ophthalmology Articles from Brightsurf:

Practice patterns, responsiveness to common ocular complaints among ophthalmology centers during COVID-19
Practice patterns for common ocular complaints during the initial stage of the COVID-19 pandemic are reported in this observational study among comprehensive U.S. ophthalmology practices.

Detection of COVID-19 viral material on environmental surfaces of an ophthalmology exam room
This study investigates the presence of SARS-CoV-2 on the environmental surfaces of an ophthalmology examination room after visits by patients who were asymptomatic and passed COVID-19 triage.

Ophthalmology after COVID-19
Changes in ophthalmology practices after the COVID-19 pandemic are discussed in this article.

Perspectives on COVID-19 control measures for ophthalmology clinics
This article describes treatment initiatives being undertaken for novel coronavirus 2019 at an ophthalmology center in Singapore.

Low risk of coronavirus spreading through tears
Study published today in the journal of the American Academy of Ophthalmology found no virus in tears of COVID-19 infected patients.

Low-cost, portable system takes OCT beyond ophthalmology
Researchers have developed a way to perform optical coherence tomography (OCT) in hard-to-reach areas of the body such as joints.

Relying on Dr. Google to diagnose eye problems may be dangerous to your health
A study examining the diagnoses generated by WebMD Symptom Checker showed the online tool was correct only 26 percent of the time.

American Academy of Ophthalmology reiterates long-standing guidance on LASIK education
The American Academy of Ophthalmology, the world's leading professional association of eye physicians and surgeons, today reiterated its long-standing guidance for patients considering LASIK vision correction surgery.

Burnout, depression can affect ophthalmology residents, study finds
A Brown University undergraduate led a JAMA Ophthalmology study showing that many ophthalmology residents face burnout and are often unable to participate in wellness initiatives, which has adverse consequences for both residents and patients.

Malcolm Gladwell published in the Journal of the American Academy of Ophthalmology
In his best sellers 'The Tipping Point,' 'Blink' and 'Outliers,' Malcolm Gladwell writes about the unexpected implications of scientific research, urging readers to think different.

Read More: Ophthalmology News and Ophthalmology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.